Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
- Conditions
- Major Depression
- Registration Number
- NCT00285766
- Lead Sponsor
- Somerset Pharmaceuticals
- Brief Summary
Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression. Subjects will have study visits (clinic visits) at beginning of study (baseline) and study weeks 1, 3, 5, 8, 12, and 16.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (15)
Mohammed Bari, M.D.
🇺🇸Chula Vista, California, United States
Charles Meredith, M.D.
🇺🇸San Diego, California, United States
Daniel Zimbroff, M.D.
🇺🇸Upland, California, United States
Kathleen Toups, M.D.
🇺🇸Walnut Creek, California, United States
Abbey Strauss, M.D.
🇺🇸Boynton Beach, Florida, United States
Barry Baumel, M.D.
🇺🇸Miami Beach, Florida, United States
Margarita Nunez, M.D.
🇺🇸St. Petersburg, Florida, United States
Mildred Farmer, M.D.
🇺🇸St. Petersburg, Florida, United States
Larry Eisner, M.D.
🇺🇸Tamarack, Florida, United States
Andrew Cutler, M.D.
🇺🇸Winter Park, Florida, United States
Scroll for more (5 remaining)Mohammed Bari, M.D.🇺🇸Chula Vista, California, United States